Regimen‐specific patterns developed: PD‐1 inhibitors were mainly applied to NSCLC and metastatic malignancies, whereas PD‐L1 inhibitors were more broadly used in relation to SCLC and extensive‐stage SCLC and end‐stage lung cancers. Here, CD274 is linked to non-small cell lung carcinoma.